GSK will invest $30 billion in U.S. research, development, and manufacturing over the next five years, a sweeping commitment that signals a shift toward more localized production and could have major implications for pharmaceutical and life sciences distributors.
The plan includes a newly announced $1.2 billion package to build advanced biopharma facilities and deploy artificial intelligence and digital technologies across the company’s U.S. operations. GSK said the projects will create hundreds of highly skilled jobs while accelerating the delivery of next-generation medicines for respiratory diseases and cancer.
“Today, we are committing to invest at least $30 billion in the United States over the next five years, further bolstering the already strong R&D and supply chain we have in the country,” said GSK Chief Executive Emma Walmsley. “$1.2 billion of today’s announcement includes construction of an additional next-gen biologics ‘flex’ factory, powered by AI, advanced technologies and expert talent to produce transformational new respiratory and cancer medicines for American patients.”
As part of the plan, GSK will build a new biologics “flex” factory at its Upper Merion, Pennsylvania campus starting in 2026. It will also expand drug substance manufacturing, device assembly, and auto-injector production while adding AI-driven systems at five sites in Pennsylvania, North Carolina, Maryland, and Montana. The company expects the U.S. to become its top market globally for clinical trials, sites, and participants over the next five years.
The commitment builds on $2 billion in U.S. manufacturing investments GSK has announced in the past year, including an $800 million facility expansion underway at its Marietta, Pennsylvania site. GSK employs about 15,000 people across the U.S. and last year delivered 1.7 billion packs of medicines and more than 400 million vaccine doses worldwide.
What It Means for Distributors
Industry analysts say the move will reverberate through pharmaceutical and healthcare distribution networks, which have faced persistent supply chain disruptions and rising demand for specialized therapies.
More stable supply: By bringing more production of biologics and injectables onshore, GSK could shorten lead times and reduce exposure to global shipping delays. Distributors may gain more predictable access to high-value medicines, improving inventory planning and customer service.
Rising cold-chain demand: The planned biologics and oncology treatments will require stringent temperature control and specialized handling. Distributors may need to expand cold-chain infrastructure, from warehouse storage to last-mile transport, to manage the influx of temperature-sensitive products.
Pressure to digitize GSK’s use of AI and digital manufacturing could accelerate production cycles and require closer coordination with supply partners. Distributors may have to invest in real-time data systems, advanced forecasting tools, and automated order management to keep pace.
Faster product launches: With GSK aiming to make the U.S. its leading market for clinical trials, the company could bring a surge of new therapies to market. Distributors able to quickly onboard and commercialize those products—particularly specialty drugs—will gain a competitive advantage.
Don’t miss any content from Distribution Strategy Group. Join our list.
